$2.51 -0.1 -2.0%
Last Trade - 05/03/21
| Market Cap | ÂŁ106.5m |
| Enterprise Value | ÂŁ42.2m |
| Revenue | ÂŁn/a |
| Position in Universe | 4682nd / 6651 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Mar | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Sio Gene Therapies Inc., together with its wholly owned subsidiaries, is a clinical-stage company focused on developing gene therapies for neurodegenerative diseases. The Company is developing a pipeline of product candidates for the treatment of these debilitating diseases, including Parkinson's disease, GM1 gangliosidosis and GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease). The Company’s subsidiaries include Axovant Holdings Ltd, Axovant Sciences Inc, Axovant Sciences GmbH, Axovant Sciences Amercia, Inc., Axovant Treasury Holdings, Inc., Axovant Treasury, Inc and Axovant Sciences Europe Ltd. The Company’s clinical-stage programs include AXO-Lenti-PD, AXO-AAV-GM1 and AXO-AAV-GM2 program.
| Last Annual | March 31st, 2020 |
| Last Interim | December 31st, 2020 |
| No. of Shareholders: | 4 |
| No. of Employees: | 38 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 58,750,611 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 130 West 42Nd Street 26Th Floor, NEW YORK, 10036, United States |
| Web | https://siogtx.com/ |
| Phone | +1 302 6365400 |
| Contact | () |
| Auditors | Ernst & Young LLP |
As of 05/03/21, shares in Sio Gene Therapies Inc are trading at $2.51, giving the company a market capitalisation of ÂŁ106.5m. This share price information is delayed by 15 minutes.
Shares in Sio Gene Therapies Inc are currently trading at $2.51 and the price has moved by -17.16% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Sio Gene Therapies Inc price has moved by -34.66% over the past year.
Of the analysts with advisory recommendations for Sio Gene Therapies Inc, there are there are currently 2 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Sio Gene Therapies Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Sio Gene Therapies Inc is scheduled to issue upcoming financial results on the following dates:
Sio Gene Therapies Inc does not currently pay a dividend.
Sio Gene Therapies Inc does not currently pay a dividend.
Sio Gene Therapies Inc does not currently pay a dividend.
To buy shares in Sio Gene Therapies Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Sio Gene Therapies Inc are currently trading at $2.51, giving the company a market capitalisation of ÂŁ106.5m.
Here are the trading details for Sio Gene Therapies Inc:
Based on an overall assessment of its quality, value and momentum, Sio Gene Therapies Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Sio Gene Therapies Inc are currently priced at $2.51. At that level they are trading at 0.254% discount to the analyst consensus target price of 0.00.
Analysts covering Sio Gene Therapies Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.888 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sio Gene Therapies Inc. Over the past six months, the relative strength of its shares against the market has been -25.28%. At the current price of $2.51, shares in Sio Gene Therapies Inc are trading at -18.61% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Sio Gene Therapies Inc.
We were unable to find the directors for Sio Gene Therapies Inc.
Here are the top five shareholders of Sio Gene Therapies Inc based on the size of their shareholding:
